Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability
The effect of proton pump inhibitors and Helicobacter pylori infection on the bioavailability of antibiotics is poorly understood. We determined the effects of 5-day oral administration of 60 mg lansoprazole on the bioavailability of clarithromycin in individuals with and without H. pylori infection...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Associação Brasileira de Divulgação Científica
2007-03-01
|
| Series: | Brazilian Journal of Medical and Biological Research |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000300014 |
| _version_ | 1819204887455465472 |
|---|---|
| author | R.A.M. Ortiz S.A. Calafatti L.A. Moraes M. Deguer C.C. Ecclissato M.A.M. Marchioretto M.L. Ribeiro G. Bernasconi J. Pedrazzoli Jr |
| author_facet | R.A.M. Ortiz S.A. Calafatti L.A. Moraes M. Deguer C.C. Ecclissato M.A.M. Marchioretto M.L. Ribeiro G. Bernasconi J. Pedrazzoli Jr |
| author_sort | R.A.M. Ortiz |
| collection | DOAJ |
| description | The effect of proton pump inhibitors and Helicobacter pylori infection on the bioavailability of antibiotics is poorly understood. We determined the effects of 5-day oral administration of 60 mg lansoprazole on the bioavailability of clarithromycin in individuals with and without H. pylori infection. Thirteen H. pylori-infected and 10 non-infected healthy volunteers were enrolled in a study with an open-randomized two-period crossover design and a 21-day washout period between phases. Plasma concentrations of clarithromycin in subjects with and without lansoprazole pre-treatment were measured by liquid chromatography coupled to a tandem mass spectrometer. Clarithromycin Cmax and AUC0-10 h were significantly reduced after lansoprazole administration. In addition, lansoprazole treatment of the H. pylori-positive group resulted in a statistically significant greater reduction in Cmax (40 vs 15%) and AUC0-10 h (30 vs 10%) compared to lansoprazole-treated H. pylori-negative subjects. Thus, treatment with lansoprazole for 5 days reduced bioavailability of clarithromycin, irrespective of H. pylori status. This reduction, however, was even more pronounced in H. pylori-infected individuals. |
| first_indexed | 2024-12-23T04:42:57Z |
| format | Article |
| id | doaj.art-43941295004c4f3a82c87c6d4ffcca40 |
| institution | Directory Open Access Journal |
| issn | 0100-879X 1414-431X |
| language | English |
| last_indexed | 2024-12-23T04:42:57Z |
| publishDate | 2007-03-01 |
| publisher | Associação Brasileira de Divulgação Científica |
| record_format | Article |
| series | Brazilian Journal of Medical and Biological Research |
| spelling | doaj.art-43941295004c4f3a82c87c6d4ffcca402022-12-21T17:59:44ZengAssociação Brasileira de Divulgação CientíficaBrazilian Journal of Medical and Biological Research0100-879X1414-431X2007-03-01403383389Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailabilityR.A.M. OrtizS.A. CalafattiL.A. MoraesM. DeguerC.C. EcclissatoM.A.M. MarchiorettoM.L. RibeiroG. BernasconiJ. Pedrazzoli JrThe effect of proton pump inhibitors and Helicobacter pylori infection on the bioavailability of antibiotics is poorly understood. We determined the effects of 5-day oral administration of 60 mg lansoprazole on the bioavailability of clarithromycin in individuals with and without H. pylori infection. Thirteen H. pylori-infected and 10 non-infected healthy volunteers were enrolled in a study with an open-randomized two-period crossover design and a 21-day washout period between phases. Plasma concentrations of clarithromycin in subjects with and without lansoprazole pre-treatment were measured by liquid chromatography coupled to a tandem mass spectrometer. Clarithromycin Cmax and AUC0-10 h were significantly reduced after lansoprazole administration. In addition, lansoprazole treatment of the H. pylori-positive group resulted in a statistically significant greater reduction in Cmax (40 vs 15%) and AUC0-10 h (30 vs 10%) compared to lansoprazole-treated H. pylori-negative subjects. Thus, treatment with lansoprazole for 5 days reduced bioavailability of clarithromycin, irrespective of H. pylori status. This reduction, however, was even more pronounced in H. pylori-infected individuals.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000300014ClarithromycinHelicobacter pyloriLansoprazolePeptic ulcerPharmacokinetics |
| spellingShingle | R.A.M. Ortiz S.A. Calafatti L.A. Moraes M. Deguer C.C. Ecclissato M.A.M. Marchioretto M.L. Ribeiro G. Bernasconi J. Pedrazzoli Jr Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability Brazilian Journal of Medical and Biological Research Clarithromycin Helicobacter pylori Lansoprazole Peptic ulcer Pharmacokinetics |
| title | Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability |
| title_full | Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability |
| title_fullStr | Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability |
| title_full_unstemmed | Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability |
| title_short | Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability |
| title_sort | effect of helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability |
| topic | Clarithromycin Helicobacter pylori Lansoprazole Peptic ulcer Pharmacokinetics |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000300014 |
| work_keys_str_mv | AT ramortiz effectofhelicobacterpyloriinfectionandacidblockadebylansoprazoleonclarithromycinbioavailability AT sacalafatti effectofhelicobacterpyloriinfectionandacidblockadebylansoprazoleonclarithromycinbioavailability AT lamoraes effectofhelicobacterpyloriinfectionandacidblockadebylansoprazoleonclarithromycinbioavailability AT mdeguer effectofhelicobacterpyloriinfectionandacidblockadebylansoprazoleonclarithromycinbioavailability AT ccecclissato effectofhelicobacterpyloriinfectionandacidblockadebylansoprazoleonclarithromycinbioavailability AT mammarchioretto effectofhelicobacterpyloriinfectionandacidblockadebylansoprazoleonclarithromycinbioavailability AT mlribeiro effectofhelicobacterpyloriinfectionandacidblockadebylansoprazoleonclarithromycinbioavailability AT gbernasconi effectofhelicobacterpyloriinfectionandacidblockadebylansoprazoleonclarithromycinbioavailability AT jpedrazzolijr effectofhelicobacterpyloriinfectionandacidblockadebylansoprazoleonclarithromycinbioavailability |